Page 199 - நாஸ்டாக் உலகளாவிய தேர்ந்தெடுக்கவும் சந்தை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

ERYTECH to Present at the H C Wainwright Virtual BioConnect 2021 Conference

Press release content from Globe Newswire. The AP news staff was not involved in its creation. ERYTECH to Present at the H.C. Wainwright Virtual BioConnect 2021 Conference Erytech Pharma S.A.January 6, 2021 GMT ERYTECH to Present at the H.C. Wainwright Virtual BioConnect 2021 Conference Lyon (France) and Cambridge, MA (U.S.), January 6, 2021 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, announced today that CEO, Gil Beyen, will present at the H.C. Wainwright Virtual BioConnect 2021 in a pre-recorded corporate overview presentation. Beginning January 11th, a pre-recorded presentation by company management will be available for on-demand viewing by registered attendees anytime through January 14th by accessing the HC Wainwright Virtual Conference portal. Those interested in registering for the conference can do so here: https://hcwev

United statesUnited kingdomFrance generalNew jerseyGil beyenNicolas merigeauEnregistrement universelPharma bioMathilde bohinCorey davisLouis victor delouvrierEric soyerCompany annual report on formExchange commissionLifesci advisorsCompany securities

IPO Lockup Expiration Alert: Nkarta Inc (NKTX)

IPO Lockup Expiration Alert: Nkarta Inc. (NKTX) BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - The lockup period of Nkarta Inc. (NKTX) expires tomorrow, i.e. on Jan 6. South San Francisco, California-based Nkarta Inc. is a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer. There are two product candidates in the pipeline - NKX101 and NKX019. NKX101 is under a phase I trial for the treatment of relapsed/refractory acute myeloid leukemia (AML) or higher risk myelodysplastic syndromes (MDS). The first patient in this trial was treated as recently as November 2020. As for NKX019, an investigational NK cell therapy engineered to target tumors expressing CD19 antigen for the treatment of B-cell malignancies, the company expects to file an Investigational New Drug (IND) Application this quarter.

Bruxelles capitaleNkarta incSan franciscoCalifornia based nkartaInvestigational new drugNasdaq global select marketப்ரூக்ஸெல்ஸ் தலைநகரம்சான் பிரான்சிஸ்கோநாஸ்டாக் உலகளாவிய தேர்ந்தெடுக்கவும் சந்தை

IPO Lockup Expiration Alert: Inventiva SA (IVA)

IPO Lockup Expiration Alert: Inventiva SA (IVA) BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - The lockup period of Inventiva SA (IVA) ends on January 6. Daix, France-based Inventiva is a clinical-stage biopharmaceutical company developing oral small molecule therapies for the treatment of non-alcoholic steatohepatitis, or NASH, mucopolysaccharidoses, or MPS, and other diseases. The company s lead drug candidate Lanifibranor for the treatment of non-alcoholic steatohepatitis (NASH), which successfully completed a phase IIb study last June, carries the FDA s Breakthrough Therapy tag. A pivotal phase III study of Lanifibranor in NASH is expected to be launched this year. The second drug candidate Odiparcil for the treatment of patients with subtypes of mucopolysaccharidoses, which has successfully completed phase IIa testing, is designated an Orphan Drug in the US and in the EU.

United statesBruxelles capitaleFrance based inventivaOrphan drugNasdaq global select marketஒன்றுபட்டது மாநிலங்களில்ப்ரூக்ஸெல்ஸ் தலைநகரம்ஆர்ஃபந் மருந்துநாஸ்டாக் உலகளாவிய தேர்ந்தெடுக்கவும் சந்தை

IPO Lockup Expiration Alert: Poseida Therapeutics (PSTX)

IPO Lockup Expiration Alert: Poseida Therapeutics (PSTX) BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - The lockup period of Poseida Therapeutics (PSTX) ends tomorrow, i.e., January 6. San Diego, California-based Poseida Therapeutics is a clinical-stage biopharmaceutical company developing cell and gene therapies to treat a range of cancers. The company s pipeline includes P-PSMA-101, a solid tumor autologous CAR-T product candidate being developed to treat patients with metastatic castrate resistant prostate cancer; P-BCMA-101, an autologous CAR-T product candidate for the treatment of patients with relapsed/refractory multiple myeloma; P-BCMA-ALLO1 for the treatment of relapsed/refractory multiple myeloma; and P-MUC1C-ALLO1, an allogeneic CAR-T product candidate with the potential to treat a wide range of solid tumors, including breast and ovarian cancers, among others.

San diegoUnited statesBruxelles capitalePoseida therapeuticsCalifornia based poseida therapeuticsNasdaq global select marketசான் டியாகோஒன்றுபட்டது மாநிலங்களில்ப்ரூக்ஸெல்ஸ் தலைநகரம்நாஸ்டாக் உலகளாவிய தேர்ந்தெடுக்கவும் சந்தை

Amdocs Management LTD: ICE Norway implementiert Advanced Network Analytics und Rollout-Optimierungssysteme von Amdocs, um die Geschäftsentwicklung zu beschleunigen und Marktanteile zu steigern

Amdocs Management LTD: ICE Norway implementiert Advanced Network Analytics und Rollout-Optimierungssysteme von Amdocs, um die Geschäftsentwicklung zu beschleunigen und Marktanteile zu steigern
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Amdocs actixoneNick boulton amdocsCampbell babelAmdocs techinsightsNetwork analyticsTechnology of amdocsServices for communicationsCompanies amdocsTechnology in amdocsProvider of softwareExchange commissionAmdocs network rolloutAmdocs management ltdIce norwayAdvanced network analyticsRadio access